Alexion Pharmaceuticals Inc named long-time Biogen Inc Chief Financial Officer Paul Clancy to a similar position, effective July 31, as recently appointed CEO Ludwig Hantson steps up efforts to regain investor confidence.
Alexion’s shares were up 3.6 percent at $111.88 in after-market trading on Tuesday.
Hantson, a former chief executive at Baxalta, was named to the top job in March after a challenging few months for the drugmaker.
Alexion said in December its then chief executive officer and chief financial officer would resign, a month after the company announced it was investigating allegations related to sales practices at its flagship drug, Soliris.
Soliris, which treats two rare blood disorders and has a U.S. list price of about $480,000 per year, is facing slowing sales growth and looming competition.
Clancy, who has been with Biogen for the past 16 years, served as CFO for the past 10 years. Prior to Biogen, he spent 13 years with PepsiCo Inc in various executive positions, Alexion said.
Clancy will succeed Dave Anderson, who will become a senior adviser to the CEO after July 31 and will remain with Alexion until the end of August, the company said.
Alexion’s shares plunged to a more than three-and-half year low last month after the company said Anderson would leave.
Clancy will remain at Biogen through the second quarter, the company said on Tuesday.
Biogen said Chief Accounting Officer Greg Covino will become the interim principal financial officer as it conducts a search for a new CFO.
By Ankur Banerjee
In 2017, Sanofi partnered with the Lebanon, New Hampshire-based ImmuNext to develop an antibody for autoimmune diseases like lupus and multiple sclerosis, which included giving Sanofi a worldwide license to develop frexalimab. The agreement involved milestone payments upto $500 million.
Global manufacturer for the pharmaceutical, biotech and nutraceutical markets, Lonza has announced that it has acquired Synaffix, a biotech company focused on the commercialisation of its clinical stage technology platform for the development of antibody-drug conjugates (ADCs).
In its hunt for the new head of its pharmaceutical systems business—which makes syringes, self-injection systems and other drug delivery devices for 70% of the top 100 drugmakers in the world, according to the company—BD landed on a candidate with plenty of experience among that customer group.